BioCardia (NSDQ:BCDA) said today that it finished treating a 10-patient cohort in its pivotal Phase III CardiAmp heart failure trial.
The company reported that it expects a review of the 30-day outcomes for this cohort in the third quarter of this year.
Get the full story at our sister site, Drug Delivery Business News.
The post BioCardia treats 10-patient cohort in late-stage heart failure trial appeared first on MassDevice.
from MassDevice http://ift.tt/2tJTCVj
Cap comentari:
Publica un comentari a l'entrada